ClinicalTrials.gg
CompletedNCT02182128Updated Jul 18, 2014

A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours

A Phase 1 interventional study of BIBF 1120 in Tumors, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-07-18.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Study summary

Confirmation of BIBF 1120 administered from 150 mg twice daily (b.i.d.) to 250 mg b.i.d. as safe and tolerable treatment in Japanese patients with advanced solid tumours, overall safety, pharmacokinetic parameters, biomarkers, and efficacy of BIBF 1120.

02

Conditions studied

  • Tumors

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 24 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients with a confirmed diagnosis of an advanced, non resectable and/or solid tumour (except for malignant lymphoma)
  2. Patients who have not responded to conventional treatment, or for whom no therapy of proven efficacy was available, or who were not amenable to established forms of treatment
  3. Patients recovered from any therapy-related toxicities from previous chemo-, hormone-, immuno-, or radio-therapies (except for epilation) at least over the following periods of time:

    • four weeks after chemotherapy (at least 2 weeks after receiving antimetabolite or at least 6 weeks after nitrosourea or mitomycin C)
    • two weeks after receiving hormone therapy
    • four weeks after receiving radiation therapy (2 weeks after radiation for symptom control)
    • two weeks after receiving immunotherapy
    • four weeks after surgical procedures
  4. Age 20 years or older
  5. of at least 3 months
  6. (ECOG) performance score of 0 to 2
  7. Patients retaining a significant physiological compensatory function and without manifest marked disorders of the hematopoietic system, heart, lung, liver, kidneys, etc., i.e., patients with sufficient baseline organ function

    • An more than 1500/mm3
    • A count more than 100000/mm3
    • A count more than 9.0 g/dL
    • Serum creatinine less than 1.5-fold the upper limit value of the normal range
    • less than 1.5-fold the upper limit value of the normal range
    • Activities of (AST) and/or alanine aminotransferase (ALT) less than 1.5-fold the upper limit value of normal range (if related to liver metastases less than 2.5-fold the upper limit value of the normal range)
    • Saturation pulse oxygen (SpO2) level not less than 90%
  8. No participation in other clinical trials within 4 weeks before start of therapy within this trial
  9. Written given that is consistent with ICH-GCP guidelines

Exclusion criteria

Exclusion criteria

  1. Brain tumour, and/or requiring therapy
  2. History of obvious pulmonary fibrosis or interstitial pneumonitis in chest X-ray including pneumoconiosis or radiation-induced pulmonary fibrosis expanding out of radiation field
  3. Patients with difficulty in swallowing study medication
  4. Gastrointestinal disorders that might interfere with the absorption of the study drug (Crohn's disease, ulcerative colitis, broad resection of the stomach)
  5. Patients with diarrhoea greater than grade 2
  6. Patients within 4 weeks after major surgical procedures or patients with active ulcers or with injuries with incomplete wound healing
  7. History of disease
  8. History of serious drug
  9. History of cardiac infarction or congested heart failure of Classification (NYHA) II or greater within previous 6 months
  10. Serious illness or concomitant non-oncological disease difficult to be controled by medication, such as active infectious disease, hepatic failure, renal failure, pulmonary fibrosis, interstitial pneumonitis, hemorrhagic tendency, heart disease (congested heart failure, angina, arrhythmia, etc.), uncontrolled, severe hypertension, and diabetes
  11. Pregnancy or breastfeeding
  12. Women and men who are sexually active and unwilling to use a medically acceptable method of until 4 weeks after the last trial visit
  13. Patients positive in tests of (HBs) antigen, (HCV)antibody, or antibody
  14. Alcohol or drug abuse
  15. Patient not suitable for participation in this clinical trial in the opinion of the investigator
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    BIBF 1120

    Drug: BIBF 1120

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Dose Limiting Toxicities (DLT) associated with increasing doses of BIBF 1120

    Time frame: Up to 36 months

  2. Incidence and intensity of Adverse Events according to Common Toxicity Criteria (CTCAE Version 3.0) associated with increasing doses of BIBF 1120

    Time frame: up to 36 months

Secondary outcomes

  1. maximum tolerated dose (MTD) of BIBF 1120

    Time frame: Up to 36 months

  2. Objective tumour response according to the response evaluation criteria in solid tumours (RECIST)

    Time frame: Up to 36 months

  3. Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 12 hours after single dose administration (AUC0-12)

    Time frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours after the first drug administration

  4. Change from baseline in peripheral blood biomarkers

    Time frame: Baseline, day 2, day 8, day 30

  5. Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 24hours after single dose administration (AUC0-24)

    Time frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration

  6. Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable analyte plasma concentration after single dose administration (AUC0-tz)

    Time frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration

  7. Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity after single dose administration (AUC0-∞)

    Time frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration

  8. The percentage of the AUCtz-∞ that is obtained by extrapolation (%AUCtz-∞)

    Time frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration

  9. Maximum measured concentration of the analyte in plasma following a single dose (Cmax)

    Time frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration

  10. Time from dosing to the maximum concentration of the analyte in plasma following a single dose (tmax)

    Time frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration

  11. Terminal half-life of the analyte in plasma after single dose administration (t1/2)

    Time frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration

  12. Terminal rate constant in plasma after single dose administration (λz)

    Time frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration

  13. Mean residence time of the analyte in the body after single dose oral administration (MRTpo)

    Time frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration

  14. Apparent clearance of the analyte in plasma after single dose extravascular administration (CL/F)

    Time frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration

  15. Apparent volume of distribution during the terminal phase λz following extravascular administration (Vz/F)

    Time frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration

  16. Area under the concentration-time curve of the analyte in plasma at steady state over the time interval from 0 to 24hours (AUC0-24,ss)

    Time frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration

  17. Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmax,ss)

    Time frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration

  18. Τime from last dosing to the maximum concentration of the analyte in plasma at steady state over a uniform dosing interval τ (tmax,ss)

    Time frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration

  19. Terminal half-life of the analyte in plasma at steady state (t1/2,ss)

    Time frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration

  20. Terminal rate constant in plasma at steady state (λz,ss)

    Time frame: Up to 36 month

  21. Minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmin,ss)

    Time frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration

  22. Predose concentration of the analyte in plasma at steady state immediately before administration of the next dose (Cpre,ss)

    Time frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration

  23. Average concentration of the analyte in plasma at steady state (Cavg)

    Time frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration

  24. Mean residence time of the analyte in the body at steady state after oral administration (MRTpo,ss)

    Time frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration

  25. Apparent clearance of the analyte in plasma at steady state after extravascular multiple dose administration (CL/F,ss)

    Time frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration

  26. Apparent volume of distribution during the terminal phase λz at steady state following extravascular administration (Vz/F,ss)

    Time frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration

  27. Accumulation ratio (RA)

    Time frame: Up to 36 month

  28. Predose concentration of the analyte in plasma immediately before administration of the n-th dose (Cpre,n)

    Time frame: Day 8, 15 and day 22 after start of treatment

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006 and a primary completion of Jun 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2014
First posted
Jul 8, 2014
Start
Jun 2006
Primary completionActual
Jun 2009
Last update
Jul 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02182128
Responsible party
Sponsor
First posted
Jul 8, 2014
Start date
Jun 2006
Primary completion
Jun 2009
Last update
Jul 18, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion